Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

First Patient Dosed in the Phase I/II Study of UC1010 for PMDD Patients

Published: Monday, May 27, 2013
Last Updated: Monday, May 27, 2013
Bookmark and Share
First patient has been dosed with UC1010 in a double-blind, multicenter study.

Umecrine Mood AB has announced that dosing has been initiated in a randomized Phase I/II study of UC1010 for the treatment of patients with premenstrual dysphoric disorder (PMDD).

Umecrine Mood is part of the Karolinska Development portfolio.

Most women experience some form of symptoms the days before menstruation but in about five percent of young and middle-aged women, the symptoms are so severe that they are considered to be suffering from PMDD.

This means that the symptoms in a debilitating way affect daily life and relationships to other people.

"The symptoms occur due to that a breakdown product of a sex hormone affect the brain's emotional center. Umecrine Mood is the first company to successfully develop compounds that are proven to reduce the activity of the breakdown product in healthy individuals. Now we take the next step to evaluate the safety and efficacy of our drug candidate in patients", says Karin Ekberg, CEO of Umecrine Mood.

The first patient has now been dosed with UC1010 in a double-blind, multicenter study in which the safety and efficacy of the product will be evaluated in a total of 120 individuals.

Principal Investigator is Professor Marie Bixo, Institute of Clinical Research and Education, Södersjukhuset, Karolinska Institutet.

"The currently available treatment of PMDD is primarily antidepressant drugs, which are not always effective and often cause side effects", says Torbjörn Bjerke, CEO of Karolinska Development AB.

Bjerke continued, "There is no doubt that these women are in need of an effective and targeted treatment, nor that the health economic benefits of being able to help the patient group would be significant."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Karolinska Development’s Dilafor Raises SEK 51 Million
The investment to facilitate Phase IIb clinical study with tafoxiparin.
Tuesday, September 27, 2016
Karolinska Development Portfolio Company Dilaforette Signs Clinical Collaboration Agreement With Arabian Gulf University
Company has signed a clinical collaboration agreement for Phase 2 clinical development of sevuparin for Sickle Cell Disease.
Tuesday, February 16, 2016
Dilaforette Initiates Phase II Clinical Trial with Sevuparin in SCD
A multi-center, double-blind, placebo-controlled study in patients experiencing vaso-occlusive crisis.
Wednesday, October 21, 2015
Dilafor Enters into a License and Partnership Agreement with Lee’s Pharmaceutical
Dilafor grants the right to manufacture, develop and commercialize tafoxiparin to Lee's Pharmaceutical.
Friday, February 21, 2014
Pergamum Announces Final Data from Phase I/II Study of LL-37
Phase I/II trial of LL-37 for treatment of patients with chronic leg ulcers.
Thursday, October 10, 2013
Lipidor Reports Positive Clinical Phase I/II Data in Psoriasis
Company is developing AKVANO®/calcipotriol for the treatment of psoriasis vulgaris.
Thursday, August 29, 2013
Pharmanest Meets All Efficacy and Safety End Points in Phase II Study of SHACT
Data show that SHACT is effective in reducing pain during IUD insertion.
Monday, August 05, 2013
Pergamum Reports Positive Data from Phase II Clinical Trial of PXL-01
Follow-up data from the Phase II clinical trial for prevention of post-surgical adhesions.
Thursday, June 27, 2013
Pharmanest Initiates Phase I Trial with SHACT
Trial is expected to enroll 15 patients and the study will be conducted at the Karolinska University Hospital.
Monday, October 15, 2012
Pergamum Reports Top Line Phase II-data from the Clinical Trial of PXL-01
The final Phase II report is expected to be published in the third quarter 2012.
Monday, August 06, 2012
Pharmanest Initiates Phase II Study of SHACT
Goal of the study is to evaluate the effect of SHACT in connection with IUD insertion in women.
Tuesday, June 19, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Gene Regulation in Brain May Explain Repetitive Behaviors in Rett Syndrome Patients
The research could be a key step in developing treatments to eliminate symptoms that drastically impair the quality of life in Rett patients.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Genetic Impact of Endurance Training
Research has found that endurance training changes genetic activity in thousands of genes, giving rise to large number of altered RNA variants.
Atmosphere Acidity Minimised to Preindustrial Levels
Sheet ice study shows acidic pollution of the atmosphere has now almost returned to preindustrial levels.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!